ANTI-CANCER PHOSPHINE CONTAINING [AuIIIm(CNC)mL]n+ COMPLEXES AND DERIVATIVES THEREOF AND METHODS FOR TREATING CANCER USING SUCH COMPOSITIONS
AssigneeThe University of Hong Kong
InventorsChi Ming Che, Raymond Wai Yin Sun, Zhen Fan Yang, Carrie Ka Lei Li
Life of this patent
Estimating the term…
Abstract
Gold(III)phosphine complexes [Aum(CNC)mL]n+ (where HCNCH=2,6-diphenylpyridine) and their use as anti-tumor agents are disclosed. Notable results for the appearance of new potential anti-tumor application of these gold(III) complexes are reported. The described complexes show promising cytotoxic properties toward cancer cells in both in vitro and in vivo studies.
Claims18
A method for treating cancer in a patient in need of such treatment, comprising administering to the patient a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a gold(III) complex having the structure I or structure II set out below:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1-R15 are each independently hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, halo, nitro, hydroxyl, alkoxyl, substituted alkoxyl, phenoxyl, substituted phenoxyl, aroxyl, substituted aroxyl, alkylthio, substituted alkylthio, phenylthio, substituted phenylthio, cyano, isocyano, substituted isocyano, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, sulfinyl, substituted sulfinyl, sulfonyl, substituted sulfonyl, sulfonic acid, substituted sulfonic acid, phosphonato, substituted phosphonato, phosphoramide, substituted phosphoramide, C1-C20 cyclic, substituted C1-C20 cyclic, heterocyclic, substituted heterocyclic, amino acid, peptide, or polypeptide group;
- L is a P-donor ligand;
- each Xp is independently a pharmaceutically acceptable counter-ion;
- m is an integer ranging from 1 to 10;
- n is an integer ranging from −10 to 100;
- p is an integer ranging from −3 to 3;
- q is equal to the absolute value of n/p;
- and
- qXp is absent when n is 0.
A pharmaceutical composition for the treatment or prophylaxis of cancer in an animal patient, the composition comprising a pharmaceutically acceptable carrier and an effective amount of gold compound having the following structure I or structure II:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1-R15 are each independently hydrogen, allyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, halo, nitro, hydroxyl, alkoxyl, substituted alkoxyl, phenoxyl, substituted phenoxyl, aroxyl, substituted aroxyl, alkylthio, substituted alkylthio, phenylthio, substituted phenylthio, cyano, isocyano, substituted isocyano, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, sulfinyl, substituted sulfinyl, sulfonyl, substituted sulfonyl, sulfonic acid, substituted sulfonic acid, phosphonato, substituted phosphonato, phosphoramide, substituted phosphoramide, C1-C20 cyclic, substituted C1-C20 cyclic, heterocyclic, substituted heterocyclic, amino acid, peptide, or polypeptide group;
- L is a P-donor ligand;
- each XP is independently a pharmaceutically acceptable counter-ion;
- m is an integer ranging from 1 to 10;
- n is an integer ranging from −10 to 100;
- p is an integer ranging from −3 to 3;
- q is equal to the absolute value of n/p;
- qXp is absent when n is 0.
2,6-diphenylpyridine-gold co-ordination complexes of formula I:
- wherein each of R1-R11 is H, m is 2, n is 2+, q is 2, Xp is (CF3SO3)− and L is a 1,2-bis(diphenylphosphino) C3-C6 alkane group.
Dependencies are inferred from the claim text.